Mesoblast (MESO) Earning Favorable Media Coverage, Accern Reports

Media stories about Mesoblast (NASDAQ:MESO) have trended positive recently, according to Accern. Accern rates the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Mesoblast earned a media sentiment score of 0.28 on Accern’s scale. Accern also gave news coverage about the company an impact score of 46.5118816538401 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

These are some of the news articles that may have impacted Accern Sentiment’s scoring:

How to Become a New Pot Stock Millionaire

Several analysts have recently commented on MESO shares. Maxim Group set a $14.00 price target on shares of Mesoblast and gave the company a “buy” rating in a research report on Thursday, March 29th. Cantor Fitzgerald set a $20.00 price target on shares of Mesoblast and gave the company a “buy” rating in a research report on Tuesday, January 16th. Zacks Investment Research upgraded shares of Mesoblast from a “hold” rating to a “buy” rating and set a $6.25 price target on the stock in a research report on Saturday, January 13th. Finally, Oppenheimer set a $16.00 price target on shares of Mesoblast and gave the company a “buy” rating in a research report on Wednesday, December 20th. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $13.54.

Shares of NASDAQ MESO opened at $5.48 on Thursday. Mesoblast has a 1 year low of $4.74 and a 1 year high of $12.50. The company has a market cap of $525.47, a P/E ratio of -5.65 and a beta of 1.95.

Mesoblast (NASDAQ:MESO) last announced its earnings results on Tuesday, February 27th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.09. Mesoblast had a negative net margin of 188.83% and a negative return on equity of 9.78%. The firm had revenue of $13.40 million for the quarter, compared to analyst estimates of $0.34 million. analysts forecast that Mesoblast will post -0.49 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This piece of content was first posted by BBNS and is the property of of BBNS. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of international trademark & copyright legislation. The legal version of this piece of content can be accessed at https://baseballnewssource.com/2018/04/05/positive-news-coverage-somewhat-unlikely-to-affect-mesoblast-meso-share-price/2024193.html.

Mesoblast Company Profile

Mesoblast Limited develops cell-based medicines. The company has leveraged its proprietary technology platform based on mesenchymal lineage adult stem cells to establish a portfolio of late-stage product candidates. Its allogeneic cell product candidates target advanced stages of diseases with high and unmet medical needs, including cardiovascular conditions, immunologic and inflammatory conditions, orthopedic disorders, and oncology and hematology conditions.

Insider Buying and Selling by Quarter for Mesoblast (NASDAQ:MESO)

Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Red Sox Tie Record for Best Start After 17 Games
Red Sox Tie Record for Best Start After 17 Games
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Rick Porcello’s Strong Start Gives Boost to Red Sox
Rick Porcello’s Strong Start Gives Boost to Red Sox
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Xander Bogaerts Goes on Red Sox DL
Xander Bogaerts Goes on Red Sox DL


Leave a Reply

 
© 2006-2018 BBNS.